WATCH LIVE
timothy sykes logo
CRSP Stock Pops As Morgan Stanley Doubles Price Target Thumbnail
G Google News

CRSP Stock Pops As Morgan Stanley Doubles Price Target

ELLIS HOBBS•UPDATED JUL. 2, 2026, 11:32 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

CRISPR Therapeutics AG stocks have been trading up by 8.09 percent amid heightened optimism over its latest gene-editing advances.

Key Takeaways

  • Morgan Stanley upgraded Crispr Therapeutics from Underweight to Equal Weight and lifted its price target from $33 to $60, a sharp reassessment of CRSP’s upside.
  • The upgrade leans on better visibility for the Casgevy launch, cleaner revenue recognition, and added value from CRISPR Therapeutics AG’s in vivo pipeline.
  • Recent Form 4 filings show insider ownership changes in CRSP, but with no details on size, direction, or context, they offer little clear trading signal.
  • Price action in CRSP has strengthened, with the stock reclaiming the $60 area after a choppy stretch in the mid‑$50s.

Candlestick Chart

Live Update At 11:31:47 EDT: On Thursday, July 02, 2026 CRISPR Therapeutics AG stock [NASDAQ: CRSP] is trending up by 8.09%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CRISPR Therapeutics AG is a classic high‑beta biotech name: tiny revenue, huge expectations. The latest quarterly numbers show just $1.46M in revenue against a net loss of about $122.9M. That’s why CRSP screens with wild margins and a sky‑high price‑to‑sales ratio. Traders are not paying for today’s income statement. They are trading the future.

On the balance sheet, CRSP carries roughly $2.73B in assets and about $911M in total liabilities, with stockholders’ equity near $1.81B. Cash and short‑term investments are strong at about $2.44B, backed by a current ratio around 18. For traders, that means CRSP has a runway to keep funding R&D and the Casgevy rollout without scrambling for cash tomorrow.

More Breaking News

The daily chart shows CRSP grinding higher. Over the last couple of weeks, the stock bounced from the low‑$50s to close near $60.12 on 2026/07/02. Intraday, the 5‑minute chart shows steady bids between $59.50 and $60.50, with an early push to $61.68 before consolidating. For active trading, CRSP is behaving like a momentum stock with defined intraday ranges and clear levels to trade against.

Why Traders Are Watching CRSP After Morgan Stanley’s Call

Morgan Stanley just flipped the script on CRISPR Therapeutics AG. The firm moved CRSP from Underweight to Equal Weight and doubled its price target from $33 to $60. That is not a small tweak. It is a full reset of how one major desk views the risk‑reward in this gene‑editing name.

The key driver is Casgevy. Morgan Stanley is telling the Street that the Casgevy launch now looks clearer, both commercially and in terms of how revenue will show up in the numbers. For traders, that matters more than any single quarter. Visibility reduces uncertainty, and when uncertainty falls, high‑growth names like CRSP often rerate higher.

CRSP also gets credit in this call for its in vivo delivery pipeline. That’s Wall Street’s way of saying the market is starting to assign real value to the platform beyond the first product. When big‑name analysts reassess a platform, momentum traders listen, because funds often rebalance around these kinds of upgrades.

At the same time, multiple Form 4 filings hit the tape, flagging changes in beneficial ownership of CRISPR Therapeutics AG shares by an insider or major holder. But the disclosures are near useless for directional trading: no details on who traded, whether it was a buy or a sell, or how big the trade was. That makes them background noise. Compared with Morgan Stanley’s fully spelled‑out thesis on Casgevy and the in vivo pipeline, these Form 4s are weak signals. For now, the real story in CRSP is the sentiment shift from the sell side and how price is responding around the $60 zone.

Conclusion

CRISPR Therapeutics AG sits at the crossroads of story and numbers. The numbers say CRSP is deeply unprofitable today, burning over $100M in operating cash in the latest quarter and posting heavy losses as it spends on research and commercialization. But the story — now backed by Morgan Stanley’s upgrade and a price‑target jump from $33 to $60 — is that Casgevy and the in vivo pipeline justify trading CRSP like a high‑growth platform, not a tiny revenue line.

For active traders, that tension creates opportunity. CRSP is liquid, volatile, and now has a fresh catalyst that big funds actually care about. The recent move from the low‑$50s into the $60 area shows that the market is already repricing. The intraday chart offers clean levels: support building in the high‑$50s, resistance near the recent $61‑plus highs.

Insider Form 4 filings in CRSP add some noise but no clear edge without details on size or direction. The smarter focus is on how price behaves around key levels as the Street digests Morgan Stanley’s new stance. As Tim Sykes loves to remind traders, “Patterns repeat, but only if you’re prepared.” As millionaire penny stock trader and teacher Tim Sykes, says, “Embrace the journey, the ups and downs; each mistake is a lesson to improve your strategy.”. CRISPR Therapeutics AG is setting up as one of those patterns right now — a catalyst‑driven biotech with strong cash, big expectations, and a chart that rewards disciplined, prepared trading.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”